top of page
vishalguptaimarc

Central Nervous System CNS Therapeutics Market Growth, Outlook 2024-2032

IMARC Group's report titled "Central Nervous System (CNS) Therapeutics Market Report by Disease (Neurodegenerative Diseases, Neurovascular Diseases, CNS Trauma, Mental Health, Infectious Diseases, CNS Cancer, and Others), Application (Hospital, Clinic, Homecare, and Others), and Region 2024-2032". offers a comprehensive analysis of the industry, which comprises insights on the global central nervous system cns therapeutics market growth. The global market size reached US$ 140.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 239.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.9% during 2024-2032.



Factors Affecting the Growth of the Central Nervous System (CNS) Therapeutics Industry:

  • Rising Prevalence of Central Nervous System (CNS) Disorders:


The increasing prevalence of neurological disorders, such as Alzheimer disease, Parkinson disease, multiple sclerosis, and epilepsy among the masses is impelling the market growth. This is attributed to factors like aging populations, lifestyle changes, and enhanced diagnostic techniques. The aging population is particularly impactful, as many CNS disorders are more common in older individuals. Additionally, the growing awareness and understanding of mental health issues are leading to higher diagnosis rates, driving the demand for effective treatments. The growing incidence of these diseases is necessitating ongoing and enhanced research and development (R&D) in CNS therapeutics.


  • Technological Advancements and Research and Development (R&D) Investments:


Technological advancements in drug development and delivery systems are supporting the market growth. Innovative approaches, such as gene therapy, biologics, and nanotechnology, are enhancing the treatment of CNS disorders. These technologies offer the potential for more effective and targeted therapies, overcoming challenges like the blood-brain barrier, which has historically limited treatment efficacy. Moreover, pharmaceutical and biotech companies are investing in developing novel therapeutics, driven by the need for more effective treatments. This influx of capital supports extensive research activities, leading to a robust ground for CNS drugs and therapies.


  • Patient Advocacy and Awareness Campaigns:


The rising number of patient advocacy groups and awareness campaigns is contributing to the market growth. These groups are instrumental in raising awareness about CNS disorders, advocating for patient rights, and promoting research funding. They act as a bridge between patients, healthcare providers, and policymakers, ensuring that the needs and challenges of patients with CNS disorders are addressed. Increasing public awareness leads to earlier diagnosis and treatment, which is driving the demand for CNS therapeutics. Moreover, advocacy groups frequently lobby for policy changes, better healthcare services, and more supportive insurance policies, creating a favorable environment for the growth of CNS therapeutics. Their efforts also help in destigmatizing mental health and neurological conditions, encouraging individuals to seek treatment.


Leading Companies Operating in the Global Central Nervous System CNS Therapeutics Industry:


  •  AstraZeneca plc

  • Biogen Inc.

  • Eli Lilly and Company

  • F. Hoffmann-La Roche AG (Roche Holding)

  • H. Lundbeck A/S

  • Merck & Co. Inc.

  • Neurocrine Biosciences Inc.

  • Novartis AG

  • Pfizer Inc.

  • Sanofi S.A.

  • Takeda Pharmaceutical Company Limited

  • Teva Pharmaceutical Industries Ltd.


Central Nervous System (CNS) Therapeutics Market Report Segmentation:


By Disease:


  • Neurodegenerative Diseases

  • Alzheimer's Disease

  • Parkinson’s Disease

  • Multiple Sclerosis

  • Huntington's Disease

  • Amyotrophic Lateral Sclerosis

  • Others 

  • Neurovascular Diseases

  • CNS Trauma

  • Mental Health

  • Anxiety Disorders

  • Epilepsy

  • Mood Disorders

  • Psychotic Disorders

  • Others

  • Infectious Diseases

  • CNS Cancer

  • Others


Neurodegenerative diseases hold the biggest market share attributed to their increasing prevalence and the growing demand for effective treatments.


By Application:


  • Hospital

  • Clinic

  • Homecare

  • Others


Based on the application, the market has been segregated into hospital, clinic, homecare, and others.


Regional Insights:


  • North America (United States, Canada)

  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

  • Latin America (Brazil, Mexico, Others)

  • Middle East and Africa


North America dominates the market due to its advanced healthcare infrastructure and rising investments in research and development (R&D).


Global Central Nervous System (CNS) Therapeutics Market Trends:


The growing integration of digital health technologies in CNS disorder management is positively influencing the market. Wearable devices, mobile health applications, and telemedicine platforms are used for monitoring patient health, managing treatments, and ensuring medication adherence. These technologies provide real-time data and insights into patient conditions, allowing for more dynamic and responsive treatment approaches. Additionally, the employment of artificial intelligence (AI) and machine learning (ML) in analyzing this data further enhances treatment personalization and effectiveness. This digitalization in healthcare is not only improving patient care but also aiding in the collection of vast amounts of data for research operations in CNS therapeutics.


Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.


About Us:


IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.


IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.


Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.


Contact US:


IMARC Group


134 N 4th St. Brooklyn, NY 11249, USA



Tel No:(D) +91 120 433 0800


United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

1 view0 comments

Comments


bottom of page